MK&A is the leading consultant to pharmaceutical, biotech, device and diagnostic companies around the world on health care constituency relations. We have one focus: building strong, productive and meaningful advocacy relations strategies that improve health, speed drug development and approval, ensure appropriate use, and provide access to patients with legitimate medical need.
We understand priorities and strengths of our clients and their potential advocacy partners and create relationships that deliver mutual benefit. Whether it’s connecting a company with key influencers, or prioritizing important patient or consumer groups in particular therapeutic areas and regions, we identify common ground that bridges the gap between our clients’ goals and the missions of key patient or professional focused organizations.
As SVP, Ellen manages clients, helps to set firm strategy, and represents the firm externally, taking her to Europe, Latin America, and the Asia Pacific region.
Ellen’s 25+ years in healthcare, including at some of the top institutions in the world, bring a range of perspectives and vantage points; she has worked with hospitals, pharmaceuticals, non-profits, and for-profits. She’s been at the bedside of patients with diseases in which MK&A’s clients are engaged, and she has developed services and programs for these patients including cancer, HIV-AIDS, rheumatology/ immunology, infectious disease, neurology and other diseases. She understands what groups need, what pharma needs, and what patients need.
She also has published and spoken on the psychosocial aspects of life-threatening illnesses.
While Ellen earned her MSW in her 20s, she remains on the cutting edge of the radically changing health care industry, recently earning a Master’s Degree from Columbia University’s executive program, in Public Health. She is a lifelong student of the human condition and brings a calm, thoughtful, and compassionate approach to MK&A and those it serves.
MK&A (Mark Krueger & Associates, Inc.) is the leading consultant to pharmaceutical, biotech, device, and diagnostic companies around the world in their quests to deliver quality care through innovative and effective partnerships with patient, consumer, and professional groups. Through its unparalleled expertise, knowledge, and global on-the-ground networks, MK&A contributes to clients’ success by speeding the development, approval, and appropriate use of and access to their products and services at the same time it builds lasting and meaningful improvements to human health.MK&A envisions a world where drugs are developed with continuous, meaningful and actionable engagement with the individuals who are most impacted by disease; patients, their advocates and their caregivers.